Sunshine Heart Provides Corporate Update

Sunshine Heart Provides Corporate Update

EDEN PRAIRIE, Minn., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc.
(Nasdaq:SSH) today provided a corporate update in advance of the 2014 J.P.
Morgan Healthcare Conference, taking place January 13 through 17 in San

The Company ended 2013 with cash and cash equivalents exceeding $54 million
and approximately 17 million common shares outstanding (unaudited). The
existing equity line of credit was unused and has $24 million remaining

As previously indicated with the release of its third quarter 2013 results,
Sunshine Heart expects revenue will be minimal until patient enrollment
reaches a predictable rate in the North American pivotal clinical trial and
reimbursement is established in select countries in Europe, which the Company
has internally modeled to begin in 2015. Sunshine Heart also expects that
quarterly operating expenses and cash burn will sequentially increase,
commensurate with further trials expansion in both the U.S. and Europe.
Quarterly non-cash compensation expense is expected to fluctuate from period
to period, based upon the timing and structure of equity awards. The Company
plans to issue its fourth quarter and full year 2013 audited results in early
March, 2014.

With respect to the European OPTIONS HF Trial, the Company completed the year
with 8 implants. With additional sites recently completing their approval
process, Sunshine Heart expects to continue to make progress on enrollment in
Europe and will provide further updates on its fourth quarter 2013 investor
call. In addition, a physician presentation including early results was
submitted for the upcoming ISHLT meeting in San Diego, taking place April 10
through 13. The Company will continue to focus on Germany, Italy and the UK
while expanding its presence to Austria and Switzerland once the centers have
approval to move forward in 2014. A response from the German authorities
regarding Sunshine Heart's NUB submission for reimbursement for the C-Pulse
System is expected in February. Given that the Company has not built any
revenue in its 2014 plan for EU reimbursement, an approval would represent
financial upside to internal guidance. Steps have also been taken to have
direct representation in Europe to provide clinical support for the OPTIONS HF
trial and any support for commercial purposes.

Regarding its U.S. Counter HF trial, Sunshine Heart finished the year with 3
enrollments, 8 activated centers, and 22 additional centers committed to
participate. The Company continues to expect to reach its goal of 35 committed
sites by the end of the first quarter 2014. 2013 enrollment is currently
tracking in line with ongoing competitive trials targeting the same patients.
As previously reported, Sunshine Heart expects to see increased activity in
2014. A pilot awareness campaign targeting patients will be launched in the
first quarter of this year at select sites to evaluate its impact in helping
expedite patient recruitment. The Company has also initiated the hiring of
therapy development specialists to focus on patient enrollment. Further
enrollment guidance will be provided once a sufficient number of centers in
the U.S. demonstrate a steady rate of enrollment. The Company continues to
target the end of 2015 to complete COUNTER HF trial enrollment and expects its
current cash to fund the enrollment of both the OPTIONS HF and COUNTER HF
trials, given the higher level of funds raised than initially targeted in the
last U.S. public financing. Results of the OPTIONS HF trial are expected to be
released by end of the second quarter of 2015.

With respect to research and development, the Company will continue to support
the development of its fully implantable program. A chronic animal trial was
successfully completed with the fully implantable device, demonstrating a
comparable level of support as the existing C-Pulse System. The Company also
expects to improve the existing technology with software and hardware
adjustments and will continue to report on pump development progress with its
TETS (Transcutaneous Energy Transmission) System through 2014. The Company has
also continued to build in-house expertise in the software and hardware
components of the C-Pulse System through additional personnel hires.

About the C-Pulse^® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device
in the United States, Canada and countries that do not recognize the CE mark
approval, utilizes the scientific principles of intra-aortic balloon
counterpulsation applied in an extra-aortic approach to assist the left
ventricle by reducing the workload required to pump blood throughout the body,
while increasing blood flow to the coronary arteries. Combined, these
potential benefits may help sustain the patient's current condition or, in
some cases, reverse the heart failure process, thereby potentially preventing
the need for later-stage heart failure devices, such as left ventricular
assist devices (LVADs), artificial hearts or transplants. It may also provide
relief from the symptoms of Class III and ambulatory Class IV heart failure
and improve quality of life and cardiac function. Based on the results from
our feasibility trial, we also believe that some patients treated with our
C-Pulse System will be able to stop using the device due to sustained
improvement in their condition as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to
Investigational use.

About Sunshine^® Heart

Sunshine Heart, Inc. (Nasdaq:SSH) is an early-stage medical device company
focused on developing, manufacturing and commercializing the C-Pulse System
for treatment of Class III and ambulatory Class IV heart failure. Sunshine
Heart has completed an approved U.S. Food and Drug Administration (FDA)
feasibility clinical trial of the C-Pulse System and presented the results in
November2011. In March 2012, the FDA notified the Company that it could move
forward with an investigational device exemption (IDE) application. Sunshine
Heart received unconditional approval from the FDA in November2012 to
initiate its pivotal trial. In July2012, Sunshine Heart received CE Mark
approval for its C-Pulse System in Europe. Sunshine Heart is a Delaware
corporation headquartered in Minneapolis with a wholly owned subsidiary in
Australia. The Company has been listed on the NASDAQ Capital Market since

Forward-Looking Statements

Certain statements in this release are forward-looking statements that are
based on management's beliefs, assumptions, expectations, and information
currently available to management. All statements that address future
operating performance, events or developments that we expect or anticipate
will occur in the future are forward-looking statements, including, without
limitation, future clinical trial activities and results including patient
enrollment in trials. These forward-looking statements are subject to numerous
risks and uncertainties, including, without limitation, the possibility that
our clinical trials do not meet their enrollment goals, meet their endpoints
or otherwise fail, that regulatory authorities do not accept our application
or approve the marketing of the C-Pulse System, the possibility that we may be
unable to raise the funds necessary for the development and commercialization
of our products, that we may not be able to commercialize our products
successfully in the EU and the other risk factors described under the caption
"Risk Factors" and elsewhere in our filings with the SEC. You should not
place undue reliance on forward-looking statements because they speak only as
of the date when made and may turn out to be inaccurate. We do not assume any
obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise. We may not
actually achieve the plans, projections or expectations disclosed in
forward-looking statements, and actual results, developments or events could
differ materially from those disclosed in the forward-looking statements.

CONTACT: For further information, please contact:
         Laura Forman
         Blueprint Life Science Group
         T: +1-415-375-3340
         Jeff Mathiesen
         Chief Financial Officer
         Sunshine Heart, Inc.
         T: +1-952-345-4200
         David Schull
         Russo Partners
         T: +1-212-845-4271
         Andreas Marathis
         Russo Partners
         T: +1-212-845-4235

Sunshine Heart logo
Press spacebar to pause and continue. Press esc to stop.